DRAFT AMENDMENTS FOR ADDENDUM 2011 OF IP 2010

UPDATED ON: 15.03.2011

The IPC has received inputs from its stakeholders on IP 2010 which require upgradation/change. The draft
amendments (PROPOSED) are put on the website (www.ipc.gov.in) for comments of the users. It is expected that if
no comments are received within 21 days, please note- the draft amendments will be taken for finalization.

2.2.9 Microbiological Contamination in Nonsterile Products

Table1. Page 39
Delete “Remarks column”

Medium 8. Rappaport Vassiliadis Salmonella Enrichment broth`

Last sentence
Change from: pH 5.2± 2 to: pH 5.2± 0.2

Medium 9. Wilson and Blair’s BBS Agar

Add the following before ‘Complete Medium’
Solution (iii) Nutrient Agar solution
Peptone 1.0g
Beef Extract 1.0g
Sodium Chloride 0.5g
Agar 2.0g
Purified water 100ml
Mix thoroughly, sterilise and cool to 45º to 50º

Medium 10. GN Broth

Last sentence
Delete: ‘Cool to 50º, mix, pour into Petri dishes.’

2.4.14 Liquid Chromatography

General. Secondary peaks
Insert the following at the end
“peaks identified as due to the counter-ion and / or other excipients including preservatives in the substance under
examination may also be excluded”

2.4.26 Solubility
Allantoin. Page 148
Change to: Slightly soluble in water; very slightly soluble in ethanol.

Lansoprazole. Page 159

Change to: Freely soluble in dimethylformamide; practically insoluble in water.

Tolterodine Tartrate. Page 170

Change from: Soluble in water. to: Slightly soluble in ethanol (95 per cent) and sparingly soluble in methanol.

Zoledronic Acid. Page 171

Change from: Sparingly soluble in water. to: Slightly soluble in water.

2.5.6 Contents of Packaged Dosage Forms. Page 194

Ointments, Creams, Pastes, Granules and Powder for Oral Liquids. Para 2, last line
Change from: labelled to: labelled amount
Para 3, line 7
Change from: 95 per cent to: 95.5 per cent
Para 3,
Insert the following at the end.
“None of individual weights deviates by more than twice that of respective minimum and maximum percentage
limits”

Liquids and suspensions. Para 4, line 9

Change from: milord to: ml or
Para 4,
Insert the following at the end.
“None of individual weights deviates by more than twice that of respective minimum and maximum percentage
limits”
Capsules, Pessaries, Suppositories and Tablets. Para 1, line 2
Change from: count to: determine
Para 2, line 1
Change from: count to: determine
Insert the following at the end.
“None of individual weights deviates by more than twice that of respective minimum and maximum percentage
limits”

4.2. GENERAL REAGENTS

Page. 569
Insert the following before Barbaloin
Azomethine H Solution. Dissolve 0.45 g of azomethine H and 1 g of ascorbic acid in water with the aid of gentle
heat and add sufficient water to produce 100 ml.

Page. 613
Insert the following before Sodium phosphate, Tribasic
Sodium phosphate, Monobasic; Sodium Biphosphate; Sodium Dihydrogen Phosphate; Acid Sodium Phosphate;
Monosodium Orthophosphate: NaH2PO4·H2O = 138.0
General reagent grade of commerce.

Tetrabutylammonium Hydroxide. Page 616

Change to: Tetrabutylammonium Hydroxide: C16H37NO,30H2O = 800

General laboratory reagent grade of commerce.

Contains not less than 98.0 per cent w/v of C16H37NO,30H2O.

Assay- Dissolve 1 g in 100 ml of water and titrate immediately with 0.1M hydrochloric acid VS determining the
end point potentiometrically.
1 ml of 0.1M hydrochloric acid VS is equivalent to 0.08 g of C16H37NO,30H2O.

Page. 621
Insert the following before Zinc, Activated
Zinc Acetate: (C2H3O2)2Zn,2H2O = 219.5
General reagent grade of commerce.
mp, about 237°.

Zinc Acetate Solution: Mix 600 ml of water with 150 ml of glacial acetic acid, add 54.9 g of zinc acetate and
stir to dissolve. Continue stirring while adding 150 ml of 13.5M ammonia , cool to room temperature, adjust to pH
6.4 with 6M ammonia and add sufficient water to produce 1000 ml.

0.25 M zinc acetate: Mix 600 ml of water with 150 ml of glacial acetic acid and 54.9 g of zinc acetate, stir to
dissolve. While stirring, add 150 ml of ammonium hydroxide, cool to room temperature, and adjust to pH of 6.4 with
ammonium hydroxide and dilute to 1000 ml with water.
MONOGRAPHS
Inhalation Preparations. Page 726
Powders for Inhalation. page 740
Delete the requirement “Uniformity of content”

Aciclovir. Page 775

Related substances. Reference solution
Change to: Reference solution. A 0.005 per cent w/v solution of 2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-
yl)methoxy]ethyl acetate RS (aciclovir impurity A RS) in dimethyl sulphoxide.

Adrenaline Tartrate. Page 778

Specific optical rotation. Line 2
Change from: 4.0 per cent w/v solution to: 4.0 per cent w/v solution of residue obtained in identification test

Amoxycillin and Potassium Clavulanate Tablets. Page.819

Assay. Chromatographic system, line 4
Change from: sodium phosphate to: sodium phosphate, monobasic.

Atorvastatin Tablets. Page 851

Related substances.
Solvent mixture. Change from: A mixture of 40 volumes of acetonitrile and 60 volumes of buffer to: A mixture of
40 volumes of acetonitrile and 60 volumes of water

Azithromycin Oral Suspension. Page 860

Related substances. Test solution, line 3
Change from: 25 ml to: 50 ml
Chromatographic system, line 16
Change from: 50 µl to: 100 µl

Betamethasone Lotion. Page 904

Usual strength
Change from: 0.05 per cent w/w to: 0.5 per cent w/v

Delete the requirement “Other tests.”

Bromhexine Hydrochloride. Page 922

Identification. B
Change from: In the test for Related Substances, the principal spot in the chromatogram obtained with test solution
(b) corresponds to that in the chromatogram obtained with reference solution (c). to: In the test for Related
Substances, the principal peak in the chromatogram obtained with the test solution corresponds to that in the
chromatogram obtained with reference solution (b).

Related substances. Reference solution (b).

Change from: Dilute 1.0 ml of the test solution to 100.0 ml with methanol. Dilute 1.0 ml of this solution to 10.0 ml
with the same solvent. to: A 0.0005 per cent w/v solution of bromhexine hydrochloride RS in methanol.

Last para, line 5

Change from: the area of one such peak is not more than to: the area of not more than one such peak is more than
Bromocriptine Mesylate. Page 923
Identification.
Change to: Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is
carried out.
A. Determine by infrared absorption spectrophotometry in a mineral oil dispersion (2.4.6). Compare the spectrum
with that obtained with bromocriptine mesylate RS or with the reference spectrum of bromocriptine mesylate.
B. Dissolve 5 mg in 5 ml of methanol and dilute to 100 ml with 0.01 M hydrochloric acid. The resulting solution,
when examined in the range 230 nm to 360 nm (2.4.7) shows an absorption maximum at about 305 nm and a
minimum at about 270 nm; absorbance at about 305 nm, 0.60 to 0.68.
C. To about 0.1 g add 5 ml of 2 M hydrochloric acid, shake for 5 minutes, filter and add 1 ml of a 6 per cent w/v
solution of barium chloride to the filtrate; it remains clear. Mix another 0.1 g with 0.5 g of anhydrous sodium
carbonate and ignite until a white residue is obtained. After cooling, dissolve the residue in 5 ml of water (solution
A); solution A gives the reactions of sulphates (2.3.1).
D. Solution A gives reaction A of bromides (2.3.1).

Change Related substances to:

Related substances. Determine by liquid chromatography (2.4.14).
Solvent mixture. A mixture of 50 volumes of chloride buffer pH 2.0 and 50 volumes of methanol.
Test solution. Dissolve 0.5 g of the substance under examination in 5.0 ml of methanol and dilute to 10.0 ml with
chloride buffer pH 2.0.
Reference solution (a). Dilute 1.0 ml of the test solution to 100.0 ml with the solvent mixture.
Reference solution (b). Dilute 1.0 ml of the reference solution (a) to 10.0 ml with the solvent mixture.
Reference solution (c). Dissolve the contents of a vial of bromocriptine mesylate for system suitability RS
(containing bromocriptine impurities A and B) in 1.0 ml of the solvent mixture.
Chromatographic system
– a stainless steel column 12 cm x 4.0 mm, packed with octadecylsilane bonded to porous silica (5µm),
– mobile phase: A. a 0.079 per cent w/v solution of ammonium carbonate,
B. acetonitrile,
– a linear gradient programme using the conditions given below,
– flow rate. 2 ml per minute,
– spectrophotometer set at 300 nm,
– injection volume. 20 µl.
Time Mobile phase A Mobile phase B
(in min.) (per cent v/v) (per cent v/v)
0-30 90- 40 10-60
30-45 40 60
Use the chromatogram supplied with bromocriptine mesylate for system suitability RS and the chromatogram
obtained with reference solution (c) to identify the peaks due to impurities A and B. The relative e retention time
with reference to bromocriptine for bromocriptine impurity c is about 1.2.
Inject reference solution (c). The test is not valid unless the resolution between the peaks due to 2-bromodehydro-α-
ergocriptine (bromocriptine impurity A) and α-ergocriptine (bromocriptine impurity B) is not less than 1.1.
Inject the test solution and reference solutions (a) and (b). In the chromatogram obtained with the test solution, the
area of any secondary peak corresponding to bromocriptine impurity A is not more than 0.2 times the area of the
principal peak in the chromatogram obtained with reference solution (b) (0.02 per cent), the area of secondary peak
corresponding to bromocriptine impurity C is not more than 4 times the area of the principal peak in the
chromatogram obtained with reference solution (b) (0.4 per cent), the area of any other secondary peak is not more
than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (0.2 per cent).
The sum of the areas of all the secondary peaks is not more than 1.5 times the area of the principal peak in the
chromatogram obtained with reference solution (a) (1.5 per cent). Ignore any peak with an area less than 0.5 times
the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent) (except the
peak due to bromocriptine impurity A).

Bromocriptine Capsules. Page 924

Related substances Change to:
Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Note- Prepare the solutions in subdued light and immediately before use. Apply the test solution as the last solution
and develop the chromatograms immediately in an unsaturated tank.
Mobile phase. A mixture of 0.1 volumes of 13.5M ammonia, 1.5 volumes of water, 3 volumes of propan-2-ol, 88
volumes of dichloromethane and 100 volumes of ether.

Test solution. Shake a quantity of the contents of the capsules containing about 20 mg of bromocriptine with 10 ml
of methanol for 20 minutes and centrifuge.
Reference solution (a). Dilute 1 ml of the test solution to 10 ml with methanol.
Reference solution (b). Dilute 3 ml of the test solution to 100 ml with methanol.
Reference solution (c). Dilute 1 ml of the test solution to 100 ml with methanol
Reference solution (d). Dilute 1 ml of the test solution to 200 ml with methanol.
Reference solution (e). A 0.023 per cent w/v solution of bromocriptine mesilate RS in methanol.
Apply to the plate 50 µl of each solution. Allow the mobile phase to rise 15 cm. Dry the plate in a current of cold air,
spray with ammonium molybdate solution and heat at 100° until bands appear (about 10 minutes). Any secondary
spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram
obtained with reference solution (b) (3.0 per cent), not more than one such secondary spot is more intense than the
chromatogram obtained with reference solution (c) (1.0 per cent) and not more than two such secondary spots are
more intense than the chromatogram obtained with reference solution (d) (0.5 per cent). Ignore the spot within 20
mm of the line of application.

Bromocriptine Tablets. Page 925

Related substances Change to:
Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Solvent mixture. Equal volumes of chloroform and methanol.

Mobile phase. A mixture of 0.1 volumes of 13.5M ammonia, 1.5 volumes of water, 3 volumes of propan-2-ol, 88
volumes of dichloromethane and 100 volumes of ether.

Test solution. Shake a quantity of the powdered tablets containing about 10 mg of bromocriptine with 25 ml of the
solvent mixture for 30 minutes, filter and wash the residue with two 5 ml quantities of the solvent mixture.
Evaporate the filtrate and washings to dryness at 25° at a pressure of 2 kPa, dissolve the residue in 2 ml of the
solvent mixture and centrifuge.

Reference solution (a). Dilute 1 ml of the test solution to 10 ml with the solvent mixture.

Reference solution (b). Dilute 3 ml of reference solution (a) to 10 ml with the solvent mixture

Reference solution (c). Dilute 1 ml of reference solution (a) to 10 ml with the solvent mixture.

Reference solution (d). Dilute 1 ml of reference solution (a) to 20 ml with the solvent mixture.

Reference solution (e). A 0.055 per cent w/v solution of bromocriptine mesilate RS in the solvent mixture.

Apply to the plate 20 µl of each solution. Allow the mobile phase to rise 15 cm. Dry the plate in air, spray with
ammonium molybdate solution and heat at 100° until spots appear ( about 10 minutes). Any secondary spot in the
chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with
reference solution (b) (3.0 per cent), not more than one such secondary spot is more intense than the spot in the
chromatogram obtained with reference solution (c) (1.0 per cent) and not more than two secondary spots are more
intense than the spot in the chromatogram obtained with reference solution (d) (0.5 per cent). Ignore the spot within
20 mm of the line of application.

Bupivacaine Hydrochloride. Page 933

Assay. Lines 3 and 6
Change from: 0.01M ethanolic sodium hydroxide to: 0.1M ethanolic sodium hydroxide

Calcitriol. Page 960

Dose.
Change from: 0.5µg to: 100 IU to 1000 IU
Assay. Chromatographic system, line 1
Change from: packed with to: packed with octadecylsilane bonded to porous silica

Calcium Carbonate. Page 961

Category.
Change to: Antacid; Pharmaceutical aid (excipient)

Calcium Stearate. Page 971

Para 2
Change to: Calcium Stearate contains the equivalent of not less than
9.0 per cent and not more than 10.5 per cent of calcium oxide (CaO). Stearic acid in the fatty acid fraction is not
less than 40.0 per cent and sum of stearic acid and palmitic acid in the fatty acid fraction is not less than 90.0 per
cent.

Insert the following before Identification

Description. A white or almost white crystalline powder.

Cefadroxil. Page 998

Related substances. After chromatographic system, para 1
Change from: Inject reference solution (c). The relative retention time with reference to cefadroxil for
dimethylformamide is about 0.4 and for dimethylacetamide is about 0.75. The test is not valid unless the resolution
between the peaks due to cefadroxil impurity A and C is not less than 5.0. In the chromatogram obtained with
reference solution (e) signal- to- noise ratio for the second peak is not less than 10. to: Inject reference solution (d).
The relative retention time with reference to cefadroxil for dimethylformamide is about 0.4 and for
dimethylacetamide is about 0.75. The test is not valid unless the resolution between the peaks due to cefadroxil
impurity A and B is not less than 5.0. In the chromatogram obtained with reference solution (e) signal- to- noise
ratio for the second peak is not less than 10

Ceftazidime. Page 1021

Change the test of Pyridine to.
Pyridine. Not more than 500 ppm.
Determine by liquid chromatography (2.4.14).
NOTE—Prepare the solutions immediately before use.
Test solution. Dissolve 0.5 g of the substance under examination in 100 ml of 10 per cent v/v solution of phosphate
buffer pH 7.0.
Reference solution (a). Dissolve 1 g of pyridine in 100.0 ml of water. Dilute 5.0 ml of this solution to 200.0 ml with
water. To 1.0 ml of the solution, add 10 ml of phosphate buffer pH 7.0 and further dilute to 100 ml with water.
 Reference solution (b). Dilute 1.0 ml of the test solution to 200.0 ml of 10 per cent v/v solution of phosphate buffer
pH 7.0. To 1.0 ml of the solution, add 20 ml of reference solution (a) and further dilute to 200 ml with a 10 per cent
v/v solution of phosphate buffer pH 7.0.
Chromatographic system
– a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
– mobile phase: a mixture of 8 volumes of 2.88 per cent w/v solution of ammonium dihydrogen orthophosphate
in water, previously adjusted to pH 7.0 with ammonia, 24 volumes of acetonitrile and 68 volumes of water,
– flow rate. 1 ml per minute,
– spectrophotometer set at 255 nm,
– injection volume. 20 µl.

Inject reference solution (b). The test is not valid unless the resolution between the peaks due to ceftazidime and
ceftazidime impurity F is not less than 7.0.
Inject reference solution (a). The test is not valid unless the relative standard deviation for replicate injections is not
more than 1.0 per cent.
Inject the test solution and reference solution (a).

Cefuroxime Sodium. Page 1028

Para 2, line 2
Change from: 90.0 per cent to: 96.0 per cent
Line 3
Change from: 105.0 per cent to: 102.0 per cent

Chlordiazepoxide. Page 1054

Related substances. After chromatographic system, Para 1 and 2
Change to: Inject reference solution (b). The test is not valid unless the resolution between the peaks due to
chlordiazepoxide impurity A and chlordiazepoxide is not less than 5.0. The relative retention time with reference to
chlordiazepoxide for 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 4-oxide (chlordiazepoxide
impurity A) is about 0.7; for 6-chloro-2-(chloromethyl)-4-phenylquinazoline 3-oxide (chlordiazepoxide impurity B)
is about 2.3; for aminochlorobenzophenone (chlordiazepoxide impurity C) is about 3.9.
Inject the test solution, reference solution (a) and (c). Run the chromatogram 6 times the retention time of the
principal peak. In the chromatogram obtained with the test solution, the area of the peak due to chlordiazepoxide
impurity A, B, for each impurity, is not more than the area of the principal peak in the chromatogram obtained with
reference solution (a) (0.2 per cent), the area of the peak due to chlordiazepoxide impurity C is not more than the
area of the principal peak in the chromatogram obtained with reference solution (c) (0.2 per cent). The area of any
other secondary peak, for each impurity, is not more than 0.5 times the area of the principal peak in the
chromatogram obtained with reference solution (a) (0.1 per cent) and sum of areas of all the secondary peaks is not
more than 2.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per
cent). Ignore any peak with an area less than 0.25 times the area of the principal peak in the chromatogram obtained
with reference solution (a) (0.05 per cent).

Chlorhexidine Gluconate Solution. Page 1057

Weight per ml. Line 1,
Change from: 20º to: 25º

Chloroquine Sulphate Tablets. Page 1066

Assay. Line 9
Change from: 0.0436 g to: 0.0209 g
Cinnarizine Tablets. Page 1090
Insert the test before Related substances.

Dissolution (2.5.2).
Apparatus No. 1,
Medium. 900 ml of gastric fluid simulated (without pepsin) TS prepared by dissolving 2.0 g of sodium chloride in
80 ml of 1M hydrochloric acid and sufficient water to make 1000 ml,
Speed and time. 100 rpm and 45 minutes.
Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate, suitably diluted if
necessary, at the maximum at about 253 nm (2.4.7). Calculate the content of C26H28N2 in the medium from the
absorbance obtained from a solution of known concentration of cinnarizine RS.
D. Not less than 70 per cent of the stated amount of C26H28N2.

Clopidogrel Bisulphate. Page 1117

Category.
Change from: Antidepressant to: Antithrombotic

Clozapine. Page 1126

Related substances. Change to:
Related substances. Determine by liquid chromatography (2.4.14).
Solvent mixture. A mixture of 20 volumes of water and 80 volumes of methanol.
Test solution. Dissolve 75 mg of the substance under examination in 80 ml of methanol and dilute to 100.0 ml with
water.
Reference solution. Dilute 1.0 ml of the test solution to 10.0 ml with the solvent mixture. Further dilute 1.0 ml of
this solution to 100.0 ml with the solvent mixture.
Chromatographic system
– a stainless steel column 12.5 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
– mobile phase: A. a mixture of 10 volumes of acetonitrile, 10 volumes of methanol and 80 volumes of buffer
solution prepared by dissolving 2.04 g of potassium dihydrogen phosphate in 1000 ml of water adjusted to pH
2.4 with orthophosphoric acid,
B. a mixture of 40 volumes of acetonitrile, 40 volumes of methanol and 20 volumes of buffer
solution prepared by dissolving 2.04 g of potassium dihydrogen phosphate in 1000 ml of water adjusted to pH
2.4 with orthophosphoric acid,
– flow rate. 1.2 ml per minute,
– a linear gradient programme using the conditions given below,
– spectrophotometer set at 257 nm,
– injection volume. 20 µl.
Time Mobile phase A Mobile phase B
(in min) (per cent v/v) (per cent v/v)
0–4 100 0
4 – 24 100 → 0 0 →100
24 – 29 0 100

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not
more than 10.0 per cent. The relative retention time with reference to clozapine for 8-chloro-11-(piperazin-1-yl)-5H-
dibenzo[b,e][1,4]diazepine (clozapine impurity C) is about 0.9, for 1-[2-[(2-amino-4-chlorophenyl)amino]benzoyl]-
4-methylpiperazine (clozapine impurity D) is about 1.1, for 8-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
11-one (clozapine impurity A) is about 1.6, for 11,11′-(piperazine-1,4-diyl)bis(8-chloro-5H-
dibenzo[b,e][1,4]diazepine) (clozapine impurity B) is about 1.7.
Inject the test solution and the reference solution. In the chromatogram obtained with the test solution, the area of
the peak due to clozapine impurity A is not more than the area of the principal peak in the chromatogram obtained
with the reference solution (0.1 per cent). The area of the peak due to clozapine impurity B and D, for each impurity,
is not more than twice the area of the principal peak in the chromatogram obtained with the reference solution (0.2
per cent), the area of the peak due to clozapine impurity C is not more than three times the area of the principal peak
in the chromatogram obtained with the reference solution (0.3 per cent). The area of other secondary peaks for each
impurity is not more than the area of the principal peak in the chromatogram obtained with the reference solution
(0.1 per cent). The sum of all the secondary peaks is not more than 6 times the area of the principal peak in the
chromatogram obtained with the reference solution (0.6 per cent). Ignore any peak with an area less than 0.5 times
the area of the principal peak in the chromatogram obtained with the reference solution (0.05 per cent).

Absorbent Cotton. Page 1137

Sulphated ash. Insert the following at the end
“using 2 ml of sulphuric acid.”

Danazol Capsules. Page 1161

Dissolution. Line 1
Change from: Apparatus No. 2 to: Apparatus No. 1

Desferrioxamine Mesylate. Page 1167

Identification
Change to:
Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.
A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with
desferrioxamine mesylate RS or with the reference spectrum of desferrioxamine mesylate.
B. Dissolve 5 mg in 5 ml of water, add 2 ml of a 0.5 per cent w/v solution of tribasic sodium phosphate, mix and
then add 0.5 ml of a 2.5 per cent w/v solution of sodium1,2- naphthoquinone-4- sulphonate; a blackish brown colour is
produced.
C. Dissolve 0.1 g in 5 ml of 2 M hydrochloric acid and add 1 ml of barium chloride solution; the solution remains
clear. In a porcelain crucible mix 0.1 g with 1 g of anhydrous sodium carbonate, heat and ignite over a Bunsen
flame. Allow to cool, dissolve the residue in 10 ml of water by heating if necessary and filter; the filtrate gives
reaction A of sulphates (2.3.1).

Desferrioxamine Injection. Page 1169

Identification
Change to:
Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with
desferrioxamine mesylate RS or with the reference spectrum of desferrioxamine mesylate.

Dextromethorphan Hydrobromide. Page 1186

Identification. C
Change from: In the test for Related substances, the principal spot in the chromatogram obtained with test solution
(b) corresponds to that in the chromatogram obtained with reference solution (c). to: In the test for Related
substances, the principal peak in the chromatogram obtained with the test solution corresponds to that in the
chromatogram obtained with the reference solution.

Related substances. Reference solution. Lines 1 and 2

Change to: A 0.0005 per cent w/v solution of dextromethorphan hydrobromide RS in the mobile phase.

Last para
Change to: Inject the test solution and the reference solution. Run the chromatogram twice the retention time of the
principal peak. In the chromatogram obtained with the test solution the area of any secondary peak is not more than
the area of the principal peak in the chromatogram obtained with the reference solution (0.5 per cent) and the area of
not more than one such peak is more than 0.5 times the area of the principal peak in the chromatogram obtained with
the reference solution (0.25 per cent). The sum of the areas of all the secondary peaks is not more than twice the area
of the principal peak in the chromatogram obtained with the reference solution (1.0 per cent). Ignore any peak with
an area less than 0.1 times the area of the principal peak in the chromatogram obtained with the reference solution
(0.05 per cent).

Diclofenac Sodium. Page.1199

Heavy metals. Line 1
Change from: 1.0 g to: 2.0 g

Diclofenac Injection. Page 1200

Assay. Change to:
Assay. Determine by liquid chromatography (2.4.14).
Test solution. Dilute a suitable volume of the injection containing 50 mg of Diclofenac Sodium to 100.0 ml with the
mobile phase. Dilute 1.0 ml of this solution to 10.0 ml with the mobile phase.
Reference solution (a). A 0.005 per cent w/v solution of diclofenac sodium RS in the mobile phase.
Reference solution (b). A solution containing 0.0005 per cent w/v of diclofenac sodium RS and 0.0005 per cent
w/v of 1-(2,6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one RS (diclofenac impurity A RS) in the mobile phase.

Chromatographic system
– a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),
– mobile phase: a mixture of 34 volumes of a mixture of equal volumes of a 0.1 per cent w/v solution of
orthophosphoric acid and a 0.16 per cent w/v solution of sodium dihydrogen orthophosphate, adjusted to pH
2.5, and 66 volumes of methanol,
– flow rate. 1 ml per minute,
– spectrophotometer set at 254 nm,
– injection volume. 10 µl.
Inject reference solution (b). The test is not valid unless the resolution between diclofenac and diclofenac impurity A
is not less than 6.5.
Inject the test solution and reference solution (a).
Calculate the content of C14H10Cl2NNaO2 in the injection.

Diclofenac Tablets. Page 1200

Assay. Change to:
Assay. Determine by liquid chromatography (2.4.14).
Test solution. Shake 10 tablets with 700 ml of methanol (50 per cent) for 30 minutes with the aid of ultrasound, add
sufficient mobile phase to produce 1000 ml, mix and filter. Dilute the filtrate with the mobile phase to produce a
solution containing 0.005 per cent w/v of Diclofenac Sodium.
Reference solution (a). A 0.005 per cent w/v solution of diclofenac sodium RS in the mobile phase.
Reference solution (b). A solution containing 0.0005 per cent w/v of diclofenac sodium RS and 0.0005 per cent
w/v of 1-(2,6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one RS (diclofenac impurity A RS) in the mobile phase.

Chromatographic system
– a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),
– mobile phase: a mixture of 34 volumes of a mixture of equal volumes of a 0.1 per cent w/v solution of
orthophosphoric acid and a 0.16 per cent w/v solution of sodium dihydrogen orthophosphate, adjusted to pH
2.5, and 66 volumes of methanol,
– flow rate. 1 ml per minute,
– spectrophotometer set at 254 nm,
– injection volume. 10 µl.
Inject reference solution (b). The test is not valid unless the resolution between diclofenac and diclofenac impurity A
is not less than 6.5.
Inject the test solution and reference solution (a).
Calculate the content of C14H10Cl2NNaO2 in the tablet.

Activated Dimethicone. Page.1230

Acidity. Line 3
Change from: 0.15 ml to: 3.0 ml

Disodium Edetate. Page 1234

Impurity A. Chromatographic system, line 2
Add the following at the end
“with a specific surface area of 120 m2/g and a pore size of 25 nm”

Iron.
Change from: Iron (2.3.14). 20 ml of a 2.5 per cent w/v solution complies with the limit test for iron (80 ppm). Add
0.25 g of calcium chloride to each solution before adding mercaptoacetic acid. to: Iron (2.3.14). 10 ml of a 1.25 per
cent w/v solution complies with the limit test for iron (80 ppm). Add 0.25 g of calcium chloride to each solution
before adding thioglycollic acid.

Docetaxel Injection. Page 1243

Para 1
Change from: The injection is constituted by dissolving the contents of the sealed container in the requisite amount
of sterile Water for Injections in accordance with the manufacturer’s instructions, immediately before use. to: The
injection is constituted by dissolving the contents of the sealed container in accordance with the manufacturer’s
instructions, immediately before use.

pH.
Change from: pH (2.4.24). 2.5 to 3.5, determined in a solution constituted as directed in the label, in 15.3 per cent
v/v solution of absolute ethanol. to: pH (2.4.24). 2.5 to 4.5, determined in a solution constituted by mixing 1 vial of
the concentrate with 15.3 per cent v/v absolute ethanol, as directed on the label.

Related substances. Test solution

Change from: Reconstitute 1 vial of sample with 1 vial of solvent. Weigh accurately 1.25 g of the reconstituted
solution and dilute to 25.0 ml with the solvent mixture. to: Reconstitute 1 vial of sample with 1 vial of solvent.
Dilute the reconstituted solution to obtain a solution containing about 0.5 mg per ml of docetaxel.

Chromatographic system, line 1

Change from: 50 cm to: 25 cm

Assay. Test solution

Change from: Reconstitute 1 vial of sample with 1 vial of solvent. Weigh accurately 1.25 g of the reconstituted
solution and dilute to 50.0 ml with the mobile phase. to: Reconstitute 1 vial of sample with 1 vial of solvent. Dilute
the reconstituted solution to obtain a solution containing about 0.25 mg per ml of docetaxel.

Chromatographic system, line 1

Change from: 50 cm to: 25 cm

Donepezil Hydrochloride. Page.1248

After structure
Change from: Mol. Wt. 415.5 to: Mol. Wt. 416

Related substances. Reference solution (a), line 1

Change from: 0.1 per cent to: 0.01 per cent
After chromatographic system
Line 3
Change from: 0.5 times to: 5 times
Line 6
Change from: twice to: 20 times

Assay. Line 6
Change from: 0.04155 to: 0.0416 per cent

Enoxaparin Sodium. Page 1276

Sodium.
Change to: Sodium. 11.3 per cent to 13.5 per cent.
Determine by atomic absorption spectrometry (2.4.2, Method A).

Test solution. Dissolve 50 mg in 0.1 M hydrochloric acid containing 0.127 per cent w/v solution of caesium
chloride and dilute to 100.0 ml with the same solvent.

Reference solutions. Prepare reference solutions (25 ppm, 50 ppm and 75 ppm) using sodium standard solution
(200 ppm Na) diluted with 0.1 M hydrochloric acid containing 0.127 per cent w/v solution of caesium chloride.

Source Sodium hollow-cathode lamp.

Wavelength 330.3 nm.

Atomisation device Flame of suitable composition (for example, 11 litres of air and 2 litres of acetylene per
minute).

Nitrogen. Line 1
Change from: 1.8 to 2.5 per cent, to: 1.8 to 2.5 per cent, Method E,

Benzyl alcohol. Internal standard solution. Line 1

Change from: 10.0 per cent to: 0.1 per cent

Enoxaparin Injection. Page.1279

Free sulphate. Line 2
Change from: liquid chromatography (2.4.14) to: ion chromatography (2.4.14)
Para 5, Chromatographic system
Change to: Chromatographic system
– a column 25 cm x 4 mm, packed with anion-exchange resin and a 5 cm x 4 mm anion-exchange guard column,
both containing ethylvinylbenzene cross linked with 55 per cent divinylbenzene with latex coating of
microbeads bonded with alkanol quaternary ammonium ions (6 per cent),
– mobile phase. a 3.0 mM sodium carbonate solution,
– flow rate. 2.0 ml per minute,
– conductivity detector,
– injection volume. 25 µl.

Anti-factor IIa activity. Line 2

Change from: mg to: ml

Escitalopram Oxalate. Page 1293

Assay. Chromatographic system, line 7
Change from: in 0.1 per cent triethylamine to: in 1000 ml of 0.1 per cent triethylamine

Escitalopram Tablets. Page 1294

Dissolution. Line 2
Change from: water to: 0.1 M hydrochloric acid
Fentanyl Injection. Page 1340
Related substances. Test solution, lines 1 and 2
Change to: dilute a volume of injection containing about 0.5mg of Fentanyl to 10.0 ml with the mobile phase, if
necessary.

Assay. Test solution, lines 1 and 2

Change to: dilute a volume of injection containing about 0.5mg of Fentanyl to 10.0 ml with the mobile phase, if
necessary.
Para 4, line 3
Change from: is not less than 2.0 to: is not more than 2.0 per cent.

Finasteride Tablets. Page 1351

Related Substances.
Reference Solution (a), lines 2, 3
Change from: Diluted 1.0 ml of this solution to 10.0 with the solvent mixture. to: Diluted 5.0 ml of this solution
to50.0 with the solvent mixture.

Uniformity of content. Test solution, line 1

Change from: 25 ml to: 2.5 ml

Fluconazole. Page 1353

Related substances. Last para, line 14
Change from: other to: all the

Folic Acid. Page 1384

Related substances. Reference solution (d), line 5
Change from: 10.0 ml to: 100.0ml

Free amines. Delete the requirement

Formoterol Fumarate and Budesonide Powder for Inhalation. Page 1387

Assay. Test solution
Change from: Test solution. To a suitable number of intact capsules add 10 ml of water and disperse with the aid of
ultrasound till the shells get disintegrated. Add 60 ml of the mobile phase and mix further with the aid of ultrasound
for 10 minutes with intermittent shaking. Add sufficient of the mobile phase to produce 100.0 ml. Dilute suitably
with the mobile phase, if required, to get a final concentration of 0.6 µg per ml of Formoterol Fumarate in the
mobile phase. to: Test solution. Dissolve a quantity of the mixed contents of
20 capsules in sufficient of the mobile phase to get a solution containing 0.6 µg of Formoterol Fumarate per ml.

Gefitinib. Page.1405
Change the Assay to:
Assay. Determine by liquid chromatography (2.4.14).
Test solution. Dissolve 10 mg of the substance under examination in 100 ml of methanol.
Reference solution. A 0.01 per cent w/v solution of gefitinib RS in the methanol.
Chromatographic system as described under Related substances.
Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not
more than 2.0 per cent.
Inject the reference solution and the test solution.
Calculate the content of C22H24O3N4FCl.

Glibenclamide. Page 1414

Identification. C, line 1
Change from: spot to: peak
Line 3
Change from: with reference solution (a). to: with the reference solution.

Related substances. Reference solution.

Change from: Reference solution. Dilute 2.0 ml of the test solution to100 ml with methanol. to: Reference solution.
A 0.00125 per cent w/v solution of glibenclamide RS in methanol.

Gliclazide. Page 1416

Heavy metals. Line 1
Change from: 1.5 g to: 2.0 g

Glimepiride. Page 1418

Impurity A. Chromatographic system, line 2
Change from: silica gel to: diol silica gel

Water
Change to: Water (2.3.43). Not more than 0.5 per cent, Method 3, determined by dissolving 0.25 g in 5.0 ml of
dimethylformamide. Carry out the test on 1.0 ml of solution. Carry out a blank test.

Glimepiride Tablets. Page 1419

Dissolution. Line 7
Change from: 15 minutes to: 30 minutes

Change the Related substances to:

Related substances. Determine by liquid chromatography (2.4.14).
NOTE— Store the solutions at a temperature not exceeding 12° and for not more than 15 hours.
Solvent mixture. 20 volumes of water and 80 volumes of acetonitrile.
Test solution. Disperse a quantity of powdered tablets containing about 5 mg of Glimepiride in 25.0 ml of the
solvent mixture.
Reference solution (a). Dissolve the contents of a vial of glimepiride for system suitability RS (containing
glimepiride impurity B, C and D) in 2.0 ml of the test solution.
Reference solution (b). Dilute 1.0 ml of the test solution to 100.0 ml with the solvent mixture. Dilute 1.0 ml of this
solution to 10.0 ml with the solvent mixture.
Chromatographic system
– a stainless steel column 25 cm x 4.0 mm, packed with endcapped octadecylsilane bonded to porous silica (4
µm),
– mobile phase: a mixture of 50 volumes of a solution prepared by dissolving 0.5 g of sodium dihydrogen
orthophosphate in 500 ml of water, adjusted to pH 2.5 with orthophosphoric acid and 50 volumes of
acetonitrile,
– flow rate. 1 ml per minute,
– spectrophotometer set at 228 nm,
– injection volume. 20 µl.

Inject reference solution (a). The test is not valid unless the resolution between the peaks due to glimepiride impurity
B and glimepiride impurity C is not less than 4.0. The relative retention time with reference to glimepiride for 3-
ethyl-4-methyl-2-oxo-N-[2-(4- sulphamoylphenyl)ethyl]-2,3-dihydro-1H-pyrrole-1-carboxamide (glimepiride
sulphonamide) (glimepiride impurity B) is about 0.2, for methyl [[4-[2-[[(3-ethyl-4-methyl-2-oxo-2, 3-dihydro-1H-
pyrrol-1-yl)carbonyl]amino]ethyl]phenyl] sulphonyl]carbamate (glimepiride urethane) (glimepiride impurity C) is
about 0.3 and for 1-[[3-[2-[[(3-ethyl-4-methyl-2-oxo-2,3-dihydro-1H-pyrrol-1-l)carbonyl]amino]ethyl]n phenyl]
sulphonyl]-3-(trans-4-methylcyclohexyl)urea (glimepiride impurity D) is about 1.1.

Inject reference solution (a), (b) and the test solution. Run the chromatogram 2.5 times the retention time of the
principal peak. In the chromatogram obtained with the test solution, the area of the peak due to glimepiride impurity
B is not more than 25 times the area of the principal peak in the chromatogram obtained with reference solution (b)
(2.5 per cent). The area of any other secondary peak is not more than 10 times the area of the principal peak in the
chromatogram obtained with reference solution (b) (1.0 per cent). The sum of all the secondary peaks other than
glimepiride impurity B is not more than 10 times the area of the principal peak in the chromatogram obtained with
reference solution (b) (1.0 per cent). The sum of all the secondary peaks is not more than 35 times the area of the
principal peak in the chromatogram obtained with reference solution (b) (3.5 per cent).

Uniformity of content. Test solution, line 1

Change from: 100 ml to: 10 ml

Guaiphenesin. Page 1430

Identification. B
Change to: When examined in the range 200 nm to 400 nm (2.4.7). A 0.004 per cent w/v solution in methanol shows
absorption maximum as obtained with the guaiphenesin RS.

Related substances. Reference solution (b). Line 2

Change from: 5.0 ml to: 0.5 ml

Reference solution (c). Lines 2 and 3

Change from: Dilute 5.0 ml of this solution to 50.0 ml with acetonitrile. to: Dilute 5.0 ml of this solution to 10.0 ml
with the test solution.

Last para, line 1

Change from: Inject the test solution and the reference solution. to: Inject the test solution, reference solutions (a)
and (b).
Line 7
Change from: not more than to: not more than twice

Heparin Sodium. Page 1439

Para 2, lines 5 to7
Delete: “and not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of heparin sodium”

Nitrogen. Line 1
Change from: 1.3 to 2.5 per cent to: Not more than 2.5 per cent

Assay. After para 7

Change from: xS= xi+(yi0.5)(xi+1xi)/(yiyi+1)
to: xs = xi+ (yi- 0.5)(xi+1- xi)/ (yi- yi+1)

Change from: M= xSxU + log R

to: M= xs - xu + log R

Hyoscine Butylbromide Injection. Page 1467

Change Assay to:

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Dilute a volume of injection containing about 40 mg of Hyoscine Butylbromide in 100.0 ml of 0.001
M hydrochloric acid.
Reference solution. A 0.04 per cent w/v solution of hyoscine butylbromide RS in 0.001 M hydrochloric acid.
Chromatographic system
– a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (10 µm) (such as
Lichrosorb C8),
– mobile phase: a buffer solution prepared by dissolving 2.0 g of sodium dodecyl sulphate in mixture of 370
volumes of 0.001 M hydrochloric acid and 680 volumes of methanol,
– flow rate. 2 ml per minute,
– spectrophotometer set at 210 nm,
– injection volume. 20 µl.
Inject the reference solution. The test is not valid unless the column efficiency is not less than 2000 theoretical
plates, tailing factor is not more than 2.0 per cent and the relative standard deviation for replicate injections is not
more than 2.0.
Inject the reference solution and the test solution.
Calculate the content of C21H30BrNO4 in the injection.

Hyoscine Butylbromide Tablets. Page 1468

Change Uniformity of content to:

Uniformity of content. Comply with the test stated under Tablets.

Determine by liquid chromatography (2.4.14), as described under Assay using following test solution.

Test solution. Disperse one intact tablet in 25.0 ml of 0.001 M hydrochloric acid, sonicate for 15 minutes and filter.

Change Assay to:

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh and powder 20 tablets. Disperse a quantity of the powder containing about 40 mg of Hyoscine
Butylbromide in 60 ml of 0.001 M hydrochloric acid, sonicate for 15 minutes, dilute to 100 ml with 0.001 M
hydrochloric acid, centrifuge and filter.
Reference solution. A 0.04 per cent w/v of solution of hyoscine butylbromide RS in 0.001 M hydrochloric acid.
Chromatographic system
– a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (10 µm) (such as
Lichrosorb C8),
– mobile phase: a buffer solution prepared by dissolving 2.0 g of sodium dodecyl sulphate in mixture of 370
volumes of 0.001 M hydrochloric acid and 680 volumes of methanol,
– flow rate. 2 ml per minute,
– spectrophotometer set at 210 nm,
– injection volume. 20 µl.

Inject the reference solution. The test is not valid unless the column efficiency is not less than 2000 theoretical
plates, tailing factor is not more than 2.0 per cent and the relative standard deviation for replicate injections is not
more than 2.0.
Inject the reference solution and the test solution.
Calculate the content of C21H30BrNO4 in the tablets.

Imipenem. Page 1486

Related substances. Solvent mixture, line 2
Change from: 1.35 per cent to: 0.0135 per cent

Imipenem and Cilastatin Injection. Page 1487

Labelling.
Change to: The label states that the constituted solution should be solubilized in a suitable parenteral fluid prior to
intravenous infusion.

Irinotecan Hydrochloride Trihydrate. Page1508

Microbial contamination. Line 1
Change from: Total aerobic microbial count to: Total viable aerobic count

Irinotecan Injection. Page 1510

Related substances. Reference solution (c), lines 4-5
Change from: solvent mixture to: mobile phase

Isoniazid. Page 1515

Hydrazine. Last para, lines 5 and 6
Change from: dimethylaminobenzeldehyde reagent to: dimethylaminobenzeldehyde solution

Ketamine Injection. Page 1539

Related substances. Last para, lines 7 and 8
Change from: the area of one such peak is not more than to: the area of not more than one such peak is more than

Ketoconazole. Page 1540

Identification.
Delete “Test B”

Line 8
Change from: C to: B

Lactulose. Page 1555

Methanol. Line 1
Delete “ Not more than 20 ppm.”

Lead. Change to:

Lead. Not more than 0.5 ppm.

Determine by atomic absorption spectrometry (2.4.2).

Solvent mixture. Equal volumes of dilute acetic acid and water.

Test solution. Dissolve 20.0 g of the substance under examination in 100 ml of the solvent mixture. Add 2.0 ml of 1
per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl ketone, shake for few
seconds protected from bright light. Allow the layers to separate and use the methyl isobutyl ketone layer.

Reference solution (a). Dissolve 0.5 ml of lead standard solution (10 ppm Pb) in 100 ml of solvent mixture. Add 2.0
ml of a clear 1 per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl
ketone , shake for few seconds and protected from bright light. Allow the layers to separate and use the methyl
isobutyl ketone layer.

Reference solution (b). Dissolve 1.0 ml of lead standard solution (10 ppm Pb) in 100 ml of solvent mixture. Add 2.0
ml of a clear 1 per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl
ketone , shake for few seconds and protected from bright light. Allow the layers to separate and use the methyl
isobutyl ketone layer.

Reference solution (c). Dissolve 1.5 ml of lead standard solution (10 ppm Pb) in 100 ml of solvent mixture. Add 2.0
ml of a clear 1 per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl
ketone , shake for few seconds and protected from bright light. Allow the layers to separate and use the methyl
isobutyl ketone layer.

Set the zero of the instrument using methyl isobutyl ketone treated as described for the test solution without the
substance under examination. Measure the absorbance at 283.3 nm using a lead hollow-cathode lamp as source of
radiation and an air- acetylene flame.

Lamivudine, Nevirapine and Stavudine Tablets. Page 1564

Dissolution. Medium
Change from: 0.01 M hydrochloric acid to: 0.1 M hydrochloric acid

Lamotrigine Sustained-release Tablets. Page 1567

Insert the following before Para 1
“Lamotrigine Sustained--release Tablets manufactured by different manufacturers, whilst complying with the
requirements of the monograph, are not interchangeable.”

Dissolution. Change to:

Dissolution (2.5.2). Complies with the test stated under tablets.

Levofloxacin Tablets. Page 1580

Related substances. Para 6, last line
Change from: not more than 2.0 to: not more than 3.0

Linezolid Tablets. Page 1591

Related substances. Chromatographic system, Mobile phase B., line 1
Change from: 90 volumes to: 10 volumes

Lisinopril. Page 1593

Specific optical rotation.
Change to: - 43.0 to – 47.0, determined on 1.0 per cent w/v solution in zinc acetate solution.

Lopinavir. Page 1602

Related substances, para 2 and 3
Change from: Test solution. Dissolve 0.1 g of the substance under examination in 100 ml of solvent mixture.
Reference solution. A 0.01 per cent w/v solution of lopinavir RS in solvent mixture.
to: Test solution. Dissolve 15 mg of the substance under examination in 100 ml of the solvent mixture.
Reference solution. A 0.015 per cent w/v solution of lopinavir RS in the solvent mixture. Dilute 1.0 ml of the
solution to 100.0 ml with the solvent mixture.

Last para
Change from: Inject separately the test solution and the reference solution. Any secondary peak should not be more
than 0.3 per cent and the sum of the areas of all the secondary peaks should not be more than 1.0 per cent when
calculated by percentage area normalisation. to: Inject the test solution and the reference solution. In the
chromatogram obtained with the test solution the area of any secondary peak is not more than 0.3 times the area of
the peak in the chromatogram obtained with the reference solution (0.3 per cent) and sum of the areas of all the
secondary peaks is not more than the area of the peak in the chromatogram obtained with the reference solution (1.0
per cent).

Light Magnesium Oxide. Page 1624

Appearance of solution. Last line
Change from: BS2 (2.3.1) to: BS2 (2.4.1)

Magnesium Stearate. Page 1625

Fatty acid composition. Chromatographic system, line 1
Change from: a stainless steel column to: a capillary column

Mannitol. Page 1633

Sulphates, line 1
Change from: 10 ml of water to: 15 ml of water

Metformin Hydrochloride Sustained-release Tablets. Page 1659

Insert the following before Para 1
“Metformin Hydrochloride Sustained-release Tablets manufactured by different manufacturers, whilst complying
with the requirements of the monograph, are not interchangeable.”

Dissolution. Change to:

Dissolution (2.5.2). Complies with the test stated under tablets.

Methylparaben. Page 1672

Para 2
Change from: Methylparaben contains not less than 99.0 per cent and not more than 101.0 per cent of C8H8O3. to:
Methylparaben contains not less than 98.0 per cent and not more than 102.0 per cent of C8H8O3.

Metronidazole Benzoate Oral Suspension. Page 1684

Usual strength.
Change from: Usual strength. 4 mg per ml; 5 mg per ml to: Usual strengths. 40 mg per ml; 50 mg per ml

Monothioglycerol. Page 1703

Refractive index.
Change from: 1.521 to 1.526 to: 1.521 to 1.526 at 25º

Montelukast Tablets. Page 1705

Para 1, line 3
Change from: C35H35ClNO3S to: C35H36ClNO3S

Dissolution. Reference solution Change to:

Reference solution. Dissolve a quantity of montelukast sodium RS in the dissolution medium and dilute with
dissolution medium to obtain a solution having a known concentration similar to the test solution.
Last line
Change from: C35H35ClNO3S to: C35H36ClNO3S

Assay. Chromatographic system line 10

Change from: 345 nm to: 240 nm
Last line
Change from: C35H35ClNO3S to: C35H36ClNO3S

Mycophenolate Mofetil. Page 1719

Related substances. Chromatographic system, line 6
Change from: 2 volumes to: 0.2 volume

Nandrolone Decanoate. Page 1750

Storage. Line 1
Change from: Store protected from light and moisture to: Store protected from light and moisture, at a temperature
between 2º to 8º.

Nelfinavir Tablets. Page 1762

Lines 3 and 4
Change from: nelfinavir mesylate,C32H45N3O4S,CH4O3S to: nelfinavir,C32H45N3O4S
Dissolution. Lines 10 and 13
Change from: C32H45N3O4S,CH4O3S to: C32H45N3O4S
Assay. Last para, last line
Change from: C32H45N3O4S,CH4O3S to: C32H45N3O4S
Neomycin Sulphate. Page 1763
Line 4
Change from: 600 Units to: 680 Units

Neomycin Eye Drops. Page 1764

Usual strength. Line 1
Change from: 0.5 per cent w/v (3500 Units per ml). to: 3500 Units per ml

Labelling.
Change from: Labelling. The strength is stated in terms of percentage w/v as well as the number of Units per ml. to:
Labelling. The strength is stated in terms of number of Units per ml.

Neomycin Eye Ointment. Page 1765

Usual strength. Line 1
Change from: 0.5 per cent w/w (3500 Units per g). to: 3500 Units per g

Labelling.
Change from: Labelling. The strength is stated in terms of percentage w/v as well as the number of Units per ml. to:
Labelling. The strength is stated in terms of number of Units per g.

Nevirapine. Page 1770

Insert the following before para 2
“Hemihydrate 275.3”
Para 2
Change to: Nevirapine is anhydrous or contains one-half molecule of water of hydration. It contains not less than
98.0 per cent and not more than 102.0 per cent of C15H14N4O, calculated on the anhydrous basis.
Loss on drying.
Change to: Water (2.3.43). Not more than 0.2 per cent for Nevirapine anhydrous and 3.1 per cent to 3.9 per cent for
Nevirapine hemihydrates.
Insert the following at the end of the monograph
“Labelling. The label states whether the material is anhydrous or hemihydrates.”

Nifedipine Tablets. Page 1782

Line 3
Delete “The tablets may be coated”

Ondansetron Oral Solution. Page 1818

Identification. A, line 2
Change from: silica gel G. to: silica gel GF254.

Related substances. Test solution

Change from: Test solution. Weigh accurately a quantity of oral solution containing about 45 mg of Ondansetron
Hydrochloride in 50-ml volumetric flask, dissolve and dilute with the mobile phase and mix. Dilute 5.0 ml of this
solution to 50 ml with the mobile phase. to: Test solution. Weigh accurately a quantity of oral solution containing
about 4.5 mg of Ondansetron Hydrochloride in 50-ml volumetric flask, dissolve and dilute with the mobile phase
and mix.

Storage.
Change from: Store protected from light and moisture. to: Store protected from light, at a temperature not exceeding
30º.

Ondansetron Orally Disintegrating Tablets. Page 1816

Insert the following before Dissolution.
Disintegration (2.5.1). Not more than 10 seconds.
Water. Delete the requirement

Ondanseteron Oral Solution. Page 1818

Related substances. Para 3, last sentence
Change from: The relative retention time with reference to ondansetron for ondansetron impurity A is
about 1.1. to: The relative retention time with reference to ondansetron for ondansetron impurity D is
about 0.34, for imidazole is about 0.4, for 2-methyl imidazole is about 0.53, for des-C-methyl ondansetron
hydrochloride is about 0.62, for N-Desmethyl ondansetron maleate is about 0.83, for ondanseteron impurity A is
about 1.2.

Oxazepam. Page 1830

Related substances. Reference solution (d). Line 1
Change from: solution (d) to: reference solution (c)

Oxytocin Injection. Page 1845

Line 3
Change from: 95.0 per cent to: 90.0 per cent
Line 4
Change from: 105.0 per cent to: 110.0 per cent

Pantoprazole Sodium. Page 1856

Related substances. Last para
Change to: Inject the test solution and the reference solution. In the chromatogram obtained with the test solution the
area of the peak due to pantoprazole impurity C determined at wavelength 305 nm at relative retention time about
0.6 is not more than 0.077 times the area of the principal peak at 290 nm in the chromatogram obtained with the
reference solution (0.5 per cent), the area of any other secondary peak is not more than 0.077 times the area of the
principal peak in the chromatogram obtained with the reference solution (0.5 per cent) and the sum of the areas of all
the secondary peaks is not more than 0.15 times the area of the principal peak in the chromatogram obtained with
the reference solution (1.0 per cent).

Storage. Line 1and 2

Change from: Store protected from light and moisture, between 2º to 8º. to: Store protected from light and moisture,
at a temperature not exceeding 30º.

Paracetamol. Page 1859

4-Aminophenol. Delete the test

Related substances. After chromatographic system, para 1 and 2

Change to: Inject reference solution (c). The test is not valid unless the resolution between the peaks due to 4-
aminophenol and paracetamol is not less than 4.0 and the signal-to-noise ratio of the peak due to chloroacetanilide
is not less than 50. The relative retention time with reference to paracetamol for 4-aminophenol is about 0.8, for 4-
nitrophenol is about 3.0 and for chloroacetanilide is about 7.0.

Inject the test solution, reference solution (a), (b), (c) and (d). Run the chromatogram 12 times the retention time of
the principal peak. In the chromatogram obtained with the test solution the area of the peak due to chloroacetanilide
is not more than 0.2 times the area of the corresponding peak in the chromatogram obtained with reference solution
(c) (10 ppm) and the area of the peak due to 4-aminophenol is not more than the area of the corresponding peak in
the chromatogram obtained with reference solution (c) (50 ppm). The area of the peak due to 4-nitrophenol is not
more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (d) (0.05
per cent).The area of any other secondary peak is not more than 0.5 times the area of the principal peak in the
chromatogram obtained with reference solution (a) (0.05 per cent). The sum of the areas of other secondary peaks is
not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent).
Ignore any peak with an area less than the area of the principal peak in the chromatogram obtained with reference
solution (b) (0.01 per cent).

Paracetamol Tablets. Page 1861

4-Aminophenol. Delete the test

Pethidine. Page 1883

Related substances.
Change to: Related substances. Determine by liquid chromatography (2.4.14).
Solvent mixture. 20 volumes of acetonitrile and 80 volumes of water.
Test solution (a). Dissolve about 0.1 g of the substance under examination in 25.0 ml of the solvent mixture.
Test solution (b). Dissolve about 0.125 g of the substance under examination in 10.0 ml of the solvent mixture.
Reference solution (a). Dilute 0.5 ml of test solution (a) to 100.0 ml with the solvent mixture.
Reference solution (b). Dissolve 10 mg of 1-methyl-4-phenylpiperidine RS (pethidine impurity A RS ) to 100.0 ml
with the solvent mixture.

Reference solution (c). Dissolve 12.5 mg of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in 10.0 ml of the solvent
mixture. Dilute 1.0 ml of this solution to 100.0 ml with the solvent mixture.
Reference solution (d). Dilute 5.0 ml of reference solution (b) and 1.0 ml of reference solution (c) to 100.0 ml with
the solvent mixture.
Chromatographic system
– a stainless steel column 25 cm x 4.0 mm packed with endcapped octadecylsilane bonded to porous silica (5
µm) (Such as Inertsil ODS2),
– mobile phase: A. a mixture of equal volumes of 4.2 per cent w/v solution of sodium perchlorate and 1.2 per
cent v/v solution of orthophosphoric acid, adjusted to pH 2.0 with triethylamine,
B. acetonitrile,
– a linear gradient programme using the conditions given below,
– flow rate. 1 ml per minute,
– spectrophotometer set at 210 nm,
– injection volume. 50 µl.
Time Mobile phase A Mobile phase B
(min.) (per cent v/v) (per cent v/v)
0 – 15 80 → 75 20 → 25
15 – 31 75 → 55 25 → 45
31 – 40 55 45
40 – 41 55 → 80 45 → 20
41 – 50 80 20
Inject reference solution (c). The test is not valid unless the signal-to-noise ratio for the first peak is not less than 10
and peak-to-valley ratio where Hp is height above the baseline, and Hv is height above the baseline of the lowest
point of the curve separating this peak from the peak due to impurity A is not less than 4.0. The relative retention
time with reference to pethidine for pethidine impurity B is about 0.66 and for pethidine impurity A is about 0.68.

Inject test solution (a), (b), reference solution (a) and (d). In the chromatogram obtained with test solution (b), the
area of the peak due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pethidine impurity B) is not more than the
area of the corresponding peak in the chromatogram obtained with reference solution (d) (10 ppm). In the
chromatogram obtained with test solution (a), the area of any secondary peak is not more than the area of the
principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent) and the sum of all the
secondary peaks is not more than twice the area of the principal peak in the chromatogram obtained with reference
solution (a) (1.0 per cent). Ignore any peak with an area less than 0.1 times the area of the principal peak in the
chromatogram obtained with reference solution (a) (0.05 per cent).
Phenoxyethanol. Page 1895
Para 1, lines 2 and 3
Delete: “calculated on the dried basis.”
Identification
Change to: A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that
obtained with phenoxyethanol RS.
B. When examined in the range 240 nm to 350 nm (2.4.7), a 0.008 per cent w/v solution in water, shows two
absorption maxima at 269 nm and 275 nm and specific absorbance at 269 nm is 95 to 105 and at 275 nm is 75 to 85.
C. Shake 2 ml of Phenoxyethanol with a mixture of 4.0 g of potassium permanganate, 5.4 g of sodium carbonate
and 75 ml of water for 30 minutes. Add 25 g of sodium chloride and stir continuously for 60 minutes, filter and
adjusted to pH 1.7 with hydrochloric acid. The melting point of the precipitate, after recrystallisation from water is
96° to 99°.

Related substances
Change to: Determine by Gas chromatography (2.4.13).
Internal standard solution. Dissolve 1.25 g of methyl laurate in 25.0 ml of dichloromethane.
Test solution (a). Dissolve 5 g of the substance under examination in 10.0 ml of dichloromethane.
Test solution (b). Dissolve 5 g of the substance under examination in 10.0 ml of dichloromethane and add 1.0 ml of
the internal standard solution.
Reference solution. Add 10.0 ml of the internal standard solution to 1.0 ml of test solution (a) and dilute to 100.0 ml
with dichloromethane.
Chromatographic system
– a glass column 1.5 m x 4 mm, packed with silanised diatomaceous earth support (150 to 180 mesh) coated
with 3 per cent w/w solution of polymethylphenyl-siloxane,
– temperature:
column. 130°,
inlet port and detector at 200°,
– flame ionization detector,
– flow rate. 30 ml per minute using nitrogen as a carrier gas.
Inject 1 µl of the reference solution. The test is not valid unless the resolution between the peaks due to
phenoxyethanol and methyl laurate is not less than 12.
Inject 1 µl of test solution (b) and the reference solution. In the chromatogram obtained with test solution (b), the
ratio of the area of the peak due to phenoxyethanol to the area of the peak due to the internal standard from the
chromatogram obtained with the reference solution; from the chromatogram obtained with test solution (b), the ratio
of the area of the sum of any secondary peak and the peak due to the internal standard is not more than 1.0 per cent.
Phenol.
Change to: Not more than 0.1 per cent.
Dissolve 1.0 g in 50 ml of dichloromethane with 1 ml of dilute sodium hydroxide solution and 10 ml of water. Wash
the upper layer with 2 quantities, each of 20 ml of dichloromethane and dilute to 100.0 ml with water. The
absorbance at the maxima at 287 nm (2.4.7) is not more than 0.27.

Phenytoin Capsules. Page 1906

Usual strength.
Change from: Usual strength. 10 mg to: Usual strengths. 25 mg, 50 mg and 100 mg

Pioglitazone Tablets. Page 1917

Assay. Reference solution, line 1
Change from: 0.015 per cent to: 0.0136 per cent
Piperacillin. Page 1918
Appearance of solution. Lines 1 and 2
Change from: carbon dioxide-free water to: sodium carbonate solution

Piroxicam. Page 1926

Related substances. After chromatographic system, para 1 and 2
Change to: Inject the reference solution. The test is not valid unless the column efficiency is not less than 5000
theoretical plates; tailing factor is not more than 2.0 per cent. The relative standard deviation for replicate injections
is not more than 2.0 per cent. The relative retention time with reference to piroxicam for piroxicam impurity B is
about 0.85.
Inject the test solution and the reference solution. Run the chromatogram 5 times the retention time of the principal
peak. In the chromatogram obtained with the test solution, the area of any secondary peak is not more than the area
of the principal peak in the chromatogram obtained with the reference solution (0.2 per cent), the sum of all the
secondary peaks is not more than twice the area of the principal peak in the chromatogram obtained with the
reference solution (0.4 per cent). Ignore any peak with an area less than 0.1 times the area of the principal peak in
the chromatogram obtained with the reference solution (0.02 per cent).

Prednisolone Sodium Phosphate. Page 1955

Para 1, line 3
Change from: on the dried basis. to: on the anhydrous basis.

Pregabalin. Page 1960

Enantiomeric purity. Para 1
Change from: Merfey’s reagent. Dissolve about 0.1502 g of merfey’s reagent in 50 ml of acetone. to: Marfey’s
reagent. Dissolve about 0.1502 g of marfey’s reagent in 50 ml of acetone.

Pregabalin Capsules. Page 1961

Related substances. Test solution.
Change from: Test solution. Mix the content of 10 capsules. Weigh and disperse a quantity containing about 15 mg
of Pregabalin, in about 25 ml of the solvent mixture, sonicate for 30 minutes and dilute to 100.0 ml with the solvent
mixture. to: Test solution. Weigh and disperse a quantity containing about 750 mg of Pregabalin, in about 25 ml of
the solvent mixture, sonicate for 30 minutes and dilute to 50.0 ml with the solvent mixture.

Last para, line 1

Change from: Inject reference solution (a) and the test solution. to: Inject reference solutions (a), (c) and the test
solution.

Propofol. Page 1985

Related substances. Last para, line 4
Change from: propofol impurity G to: propofol impurity G, multiplied with relative response factor 5.0
Line 7
Change from: propofol impurity E to: propofol impurity E, multiplied with relative response factor 0.25

Propylparaben. Page 1991

Para 2
Change from: Propylparaben contains not less than 99.0 per cent and not more than 101.0 per cent of C10H12O3,
calculated on the dried basis. to: Propylparaben contains not less than 98.0 per cent and not more than 102.0 per cent
of C10H12O3, calculated on the dried basis.
Pyrazinamide. Page 2004
Water.
Change from: (2.4.19) to: (2.3.43)

Quetiapine Tablets. Page 2014

Para 1, line 3
Change from: C21H25N3O2S to: C42H50N6O4S2

Assay. Last line

Change from: C21H25N3O2S to: C42H50N6O4S2

Rabeprazole Tablets. Page 2037

Change Dissolution to:
Dissolution (2.5.2).
A. Apparatus No. 1,
Medium. 900 ml of 0.1 M hydrochloric acid,
Speed and time. 50 rpm and 120 minutes.
Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtered solution immediately,
suitably diluted with the dissolution medium, if necessary, at the maximum at about 291 nm (2.4.7). Calculate the
content of C18H20N3O3SNa in the medium from the absorbance obtained from a solution of known concentration
of rabeprazole sodium RS, prepared by dissolving in minimum quantity of a mixture of 75 volumes of acetonitrile
and 25 volumes of methanol and suitably diluted with the dissolution medium.
D. Not less than 10 per cent of the stated amount of C18H20N3O3SNa.
B. Apparatus No. 1,
Medium. 900 ml of phosphate buffer pH 7.4 prepared by dissolving 5.8 g of potassium dihydrogen phosphate in
1000 ml of water, adjusted to pH 7.4 with sodium hydroxide solution.
Speed and time. 75 rpm and 45 minutes.
Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtered solution immediately,
suitably diluted with the dissolution medium, if necessary, at the maximum at about 291 nm (2.4.7). Calculate the
content of C18H20N3O3SNa in the medium from the absorbance obtained from a solution of known concentration
of rabeprazole sodium RS, prepared by dissolving in minimum quantity of a mixture of 75 volumes of acetonitrile
and 25 volumes of methanol and suitably diluted with the dissolution medium.
D. Not less than 70 per cent of the stated amount of C18H20N3O3SNa.

Serratiopeptidase. Page 2097

Identification. Line 4
Change from: 0.04 ml to: 0.04 M

Microbial contamination. Lines 2 and 3

Change from: 1 ml to: 1 g

Assay. Line 2
Change from: 1 µm to: 1 µg

Protein precipitating solution, line 3

Change from: 100 ml to: 1000 ml

Reference tyrosine curve. Line 5

Change from: sodium carbonate solution to: 6.0 per cent w/v sodium carbonate solution

Test solution. Line 7

Change from: 0.6 per cent to: 6.0 per cent

Blank solution, line 6

Change from: 50 ml of 0.6 per cent to: 5 ml of 6.0 per cent
Sildenafil Tablets. Page 2101
Para 1, lines 2 and 3
Change from: sildenafil citrate, C28H38N6O11S. to: sildenafil, C22H30N6O4S.

Dissolution. Lines 7 and 11

Change from: C28H38N6O11S to: C22H30N6O4S

Assay. Last line

Change from: C28H38N6O11S to: C22H30N6O4S

Simvastatin Tablets. Page 2104

Dissolution. Line 13
Change from: minimum at about 257 nm to: minimum at about 247 nm

Assay. Test solution.

Change from: Test solution. Disperse a quantity of whole tablets containing about 0.16 g of Simvastatin in water
and mix with the aid of ultrasound and shaking. Add sufficient of solution A to produce about 75 ml, mix with the
aid of ultrasound and shaking for 15 minutes, dilute to 100 ml with solution A and centrifuge. Dilute 1 ml of the
clear supernatant solution with sufficient of solution A to produce a solution containing 0.01 per cent
w/v of Simvastatin. to: Test solution. Weigh and powder 20 tablets. Weigh a quantity of the powder containing
about 100 mg of Simvastatin, disperse in 100 ml of solution A and filter. Dilute 5.0 ml of the solution to 50.0 ml
with solution A.

Salbutamol. Page 2083

Identification. C
Change to: In the test for Related substances, the principal peak in the chromatogram obtained with the test solution
corresponds to the peak due to salbutamol that in the chromatogram obtained with the reference solution.

Related substances. Reference solution, line 1

Change from: 0.02 per cent to: 0.03 per cent

Salbutamol Sulphate. Page 2085

Identification. C
Change to: In the test for Related substances, the principal peak in the chromatogram obtained with the test solution
corresponds to the peak due to salbutamol that in the chromatogram obtained with the reference solution.

Related substances. Reference solution, line 1

Change from: 0.02 per cent to: 0.03 per cent

Simvastatin. Page 2103

Assay. After chromatographic system, line 3
Change from: not less than 5.0. to: not less than 4.0.

Sodium Fusidate. Page 2123

Identification. B
Test B: Delete the test
Test C
Change from: C to: B.

Sodium Methylparaben. Page 2132

Identification. B
Change to: A 5 per cent w/v solution gives the reactions of sodium salts (2.3.1).
Sorbic Acid. Page 2141
Heavy metals.
Change to: 12 ml of 10 per cent w/v solution in ethanol (95 per cent) complies with the test for heavy metals,
Method D (10 ppm).

Sorbitol Solution (70 Per cent)

(Crystallising) Monograph change to:
Sorbitol Solution (70 Per cent) (Crystallising)
Sorbitol (70 per cent) (Crystallising)
Sorbitol Solution (70 per cent) (Crystallising) is an aqueous solution of hydrogenated, partly hydrolysed starch.
Sorbitol Solution (70 per cent) (Crystallising) contains not less than 68.0 per cent m/m and not more than 72.0 per
cent m/m of anhydrous substances and not less than 92.0 per cent w/w and not more than 101.0 per cent w/w of D-
glucitol, C6H14O6, ), calculated on the anhydrous basis.
Category. Pharmaceutical aid.
Description. A clear, colourless , syrupy liquid, miscible with water.
Identification
A. In the Assay, the principle peak in the chromatogram obtained with the test solution corresponds to the peak in
the chromatogram obtained with reference solution (a).
B. To 7.0 g, add 40 ml of water and 6.4 g of disodium tetraborate. Allow to stand for 1 hour, shake occasionally and
dilute to 50.0 ml with water. The angle of rotation (2.4.22) is +0° to +1.5°.
C. It is clear syrupy liquid at 25°.
Tests
Appearance of solution. A 14.0 per cent w/v solution in water is clear (2.4.1), and colourless (2.4.1).
Conductivity (2.4.9). Not more than 10 µS cm–1, measured on undiluted liquid sorbitol (crystallizing) while gently
stirring with a magnetic stirrer.
Reducing sugars. Not more than 0.2 per cent, calculated as glucose equivalent.
To 5.0 g add 6.0 ml of water, 20.0 ml of cupri-citric solution and a few glass beads. Heat so that boiling begins after
4 minutes and maintain boiling for 3 minutes. Cool rapidly and add 100.0 ml of a 2.4 per cent v/v solution of glacial
acetic acid and 20.0 ml of 0.025 M iodine. With continuous shaking, add 25.0 ml of a mixture of 6 volumes of
hydrochloric acid and 94 volumes of water and when the precipitate has dissolved, titrate the excess of iodine with
0.05 M sodium thiosulphate using 1 ml of starch solution, added towards the end of the titration, as indicator. Not
less than 12.8 ml of 0.05 M sodium thiosulphate is required.
Lead. Not more than 0.5 ppm.
Determine by atomic absorption spectrometry (2.4.2), Method A.

Solvent mixture. Equal volumes of dilute acetic acid and water.

Test solution. Dissolve 20.0 g of the substance under examination in 100 ml of the solvent mixture. Add 2.0 ml of 1
per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl ketone, shake for few
seconds protected from bright light. Allow the layers to separate and use the methyl isobutyl ketone layer.

Reference solution (a). Dissolve 0.5 ml of lead standard solution (10 ppm Pb) in 100 ml of solvent mixture. Add 2.0
ml of a clear 1 per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl
ketone , shake for few seconds and protected from bright light. Allow the layers to separate and use the methyl
isobutyl ketone layer.

Reference solution (b). Dissolve 1.0 ml of lead standard solution (10 ppm Pb) in 100 ml of solvent mixture. Add 2.0
ml of a clear 1 per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl
ketone , shake for few seconds and protected from bright light. Allow the layers to separate and use the methyl
isobutyl ketone layer.
Reference solution (c). Dissolve 1.5 ml of lead standard solution (10 ppm Pb) in 100 ml of solvent mixture. Add 2.0
ml of a clear 1 per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl
ketone , shake for few seconds and protected from bright light. Allow the layers to separate and use the methyl
isobutyl ketone layer.

Set the zero of the instrument using methyl isobutyl ketone treated as described for the test solution without the
substance under examination. Measure the absorbance at 283.3 nm using a lead hollow-cathode lamp as source of
radiation and an air- acetylene flame.

Nickel. Dissolve 10.0 g in sufficient water to produce 20 ml, add 3.0 ml of bromine water and 2.0 ml of a 20 per
cent w/v solution of citric acid, mix and add 10.0 ml of 6 M ammonia and 1.0 ml of a 1.0 per cent w/v solution of
dimethylglyoxime in ethanol (95 per cent). Mix, dilute to 50.0 ml with water and allow to stand for 5 minutes; any
colour produced is not more intense than that produced by treating in the same manner and at the same time 1.0 ml
of nickel standard solution (10 ppm Ni) diluted to 20.0 ml with water (1 ppm).
Water (2.3.43). 28.0 per cent to 32.0 per cent, determined on 0.1 g.
Assay. Determine by liquid chromatography (2.4.14).
Test solution. Dissolve 1.0 g of the substance under examination in 50.0 ml of water.
Reference solution (a). Dissolve 65 mg of sorbitol RS in 5.0 ml of water.
Reference solution (b). Dissolve 65 mg of mannitol and 65 mg of sorbitol in 5.0 ml of water.
Chromatographic system
– a stainless steel column 30 cm x 7.8 mm, packed with strong cation exchange resin (calcium form) (9 µm),
– column temperature. 85°,
– mobile phase: water,
– flow rate. 0.5 ml per minute,
– refractometer set at a constant temperature,
– injection volume. 20 µl.
Inject reference solution (b). The test is not valid unless the resolution between the peaks due to sorbitol and
mannitol is not less than 2.0. The relative retention time with reference to sorbitol (Retention time is about 27
minutes) for mannitol is about 0.8.
Inject the test solution and reference solution (a). Run the chromatogram for three times the retention time of
sorbitol.
Calculate the content of D-sorbitol, C6H14O6.
Storage. Store protected from moisture.

Sorbitol Solution (70 Per cent)

(Non-Crystallising) Monograph change to:
Sorbitol Solution (70 Per cent)
(Non-Crystallising)
Sorbitol (70 per cent) (Non-crystallising)
Sorbitol Solution (70 per cent) (Non-crystallising) is an aqueous solution of hydrogenated, partly hydrolysed starch.
Sorbitol Solution (70 per cent) (Non-crystallising) contains not less than 68.0 per cent m/m and not more than 72.0
per cent m/m of anhydrous substances and not less than 72.0 per cent w/w and not more than 92.0 per cent w/w of
D-glucitol, C6H14O6, calculated on the anhydrous basis.
Category. Pharmaceutical aid (sweetening vehicle); humectant.
Description. A clear, colourless or faintly yellow, syrupy liquid.
Identification
A. In the Assay, the principle peak in the chromatogram obtained with the test solution corresponds to the peak in
the chromatogram obtained with reference solution (a).
B. To 7.0 g add 40 ml of water and 6.4 g of disodium tetraborate. Allow to stand for 1 hour, shake occasionally and
dilute to 50.0 ml with water. The angle of rotation (2.4.22) is +1.5° to +3.5°.
C. It is clear syrupy liquid at 25°.
Tests
Appearance of solution. A 14.0 per cent w/v solution in water is clear (2.4.1), and colourless (2.4.1).
Conductivity (2.4.9). Not more than 10 µS cm–1, measured on undiluted liquid sorbitol while gently stirring with a
magnetic stirrer.
Reducing sugars. Not more than 0.2 per cent, calculated as glucose equivalent.
To 5.0 g add 6.0 ml of water, 20.0 ml of cupri-citric solution and a few glass beads. Heat so that boiling begins after
4 minutes and maintain boiling for 3 minutes. Cool rapidly and add 100.0 ml of a 2.4 per cent v/v solution of glacial
acetic acid and 20.0 ml of 0.025 M iodine. With continuous shaking, add 25.0 ml of a mixture of 6 volumes of
hydrochloric acid and 94 volumes of water and when the precipitate has dissolved, titrate the excess of iodine with
0.05 M sodium thiosulphate using 1 ml of starch solution, added towards the end of the titration, as indicator. Not
less than 12.8 ml of 0.05 M sodium thiosulphate is required.
Reducing sugars after hydrolysis. Not more than 9.3 per cent, calculated as glucose equivalent.
To 6.0 g add 35 ml of water, 40 ml of 1 M Hydrochloric acid and a few glass beads. Reflux for 4 hours. Cool and
neutralize with dilute sodium hydroxide solution using 0.2 ml of bromothymol blue solution as indicator. Cool and
dilute to 100.0 ml with water. To 3.0 ml of the solution add 5.0 ml of water, 20 ml of cupri-citric solution and a few
glass beads. Heat so that boiling begins after 4 minutes and maintain boiling for 3 minutes. Cool rapidly and add 100
ml of a 2.4 per cent v/v solution of glacial acetic acid and 20.0 ml of 0.025 M iodine. With continuous shaking, add
25 ml of a mixture of 6 volumes of hydrochloric acid and 94 volumes of water and when the precipitate has
dissolved, titrate the excess of iodine with 0.05 M sodium thiosulphate using 1 ml of starch solution, added towards
the end of the titration, as indicator. Not less than 8.0 ml of 0.05 M sodium thiosulphate is required.
Lead. Not more than 0.5 ppm.
Determine by atomic absorption spectrometry (2.4.2).

Solvent mixture. Equal volumes of dilute acetic acid and water.

Test solution. Dissolve 20.0 g of the substance under examination in 100 ml of the solvent mixture. Add 2.0 ml of 1
per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl ketone, shake for few
seconds protected from bright light. Allow the layers to separate and use the methyl isobutyl ketone layer.

Reference solution (a). Dissolve 0.5 ml of lead standard solution (10 ppm Pb) in 100 ml of solvent mixture. Add 2.0
ml of a clear 1 per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl
ketone , shake for few seconds and protected from bright light. Allow the layers to separate and use the methyl
isobutyl ketone layer.

Reference solution (b). Dissolve 1.0 ml of lead standard solution (10 ppm Pb) in 100 ml of solvent mixture. Add 2.0
ml of a clear 1 per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl
ketone , shake for few seconds and protected from bright light. Allow the layers to separate and use the methyl
isobutyl ketone layer.

Reference solution (c). Dissolve 1.5 ml of lead standard solution (10 ppm Pb) in 100 ml of solvent mixture. Add 2.0
ml of a clear 1 per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl
ketone , shake for few seconds and protected from bright light. Allow the layers to separate and use the methyl
isobutyl ketone layer.

Set the zero of the instrument using methyl isobutyl ketone treated as described for the test solution without the
substance under examination. Measure the absorbance at 283.3 nm using a lead hollow-cathode lamp as source of
radiation and an air- acetylene flame.

Nickel. Dissolve 10.0 g in sufficient water to produce 20 ml, add 3.0 ml of bromine water and 2.0 ml of a 20 per
cent w/v solution of citric acid, mix and add 10.0 ml of 6 M ammonia and 1.0 ml of a 1.0 per cent w/v solution of
dimethylglyoxime in ethanol (95 per cent). Mix, dilute to 50.0 ml with water and allow to stand for 5 minutes; any
colour produced is not more intense than that produced by treating in the same manner and at the same time 1.0 ml
of nickel standard solution (10 ppm Ni) diluted to 20.0 ml with water (1 ppm).
Water (2.3.43). 28.0 per cent to 32.0 per cent, determined on 0.1 g.
Assay. Determine by liquid chromatography (2.4.14).
Test solution. Dissolve 1.0 g of the substance under examination in 50.0 ml of water.
Reference solution (a). Dissolve 55 mg of sorbitol RS in 5.0 ml of water.
Reference solution (b). Dissolve 55 mg of mannitol and 55 mg of sorbitol in 5.0 ml of water.
Chromatographic system
– a stainless steel column 30 cm x 7.8 mm, packed with strong cation exchange resin (calcium form) (9 µm),
– column temperature. 85°,
– mobile phase: water,
– flow rate. 0.5 ml per minute,
– refractometer set at a constant temperature,
– injection volume. 20 µl.
Inject reference solution (b). The test is not valid unless the resolution between the peaks due to sorbitol and
mannitol is not less than 2.0. The relative retention time with reference to sorbitol (Retention time is about 27
minutes) for mannitol is about 0.8.
Inject the test solution and reference solution (a). Run the chromatogram for three times the retention time of
sorbitol.
Calculate the content of D-sorbitol, C6H14O6.
Storage. Store protected from moisture.

Stavudine. Page 2149

Assay. Reference solution (a), line 3
Change from: α-thymidine to: β-thymidine
After chromatographic system, line 3
Change from: α-thymidine to: β-thymidine

Stearic Acid. Page 2154

Change Assay to:
Assay. Determine by gas chromatography (2.4.13).
Test solution. Dissolve 0.1 g of substance under examination in 5 ml of boron trifluoride-methanol solution in a
conical flask fitted with a reflux condenser. Reflux for 10 minutes, add 4.0 ml of heptane through the condenser and
boil again for 10 minutes. Allow to cool, add 20 ml of a saturated solution of sodium chloride. Shake and allow the
layers to separate. Remove about 2 ml of the organic layer and dry it over 0.2 g of anhydrous sodium sulphate.
Dilute 1.0 ml of this solution to 10.0 ml with heptane.
Reference solution. Dissolve 50 mg of palmitic acid RS and 50 mg of stearic acid RS in 5 ml of boron trifluoride-
methanol solution in a conical flask fitted with a reflux condenser. Reflux for 10 minutes, add 4.0 ml of heptane
through the condenser and boil again for 10 minutes. Allow to cool, add 20 ml of a saturated solution of sodium
chloride. Shake and allow the layers to separate. Remove about 2 ml of the organic layer and dry it over 0.2 g of
anhydrous sodium sulphate. Dilute 1.0 ml of this solution to 10.0 ml with heptane.
Chromatographic system
– a fused-silica column 30 m x 0.32 mm, packed with macrogol 20000 (0.5 µm),
– temperature:
column 70° from 0 to 2 minutes, 70° - 240° from 2 to 36 minutes and hold at 240° from 36 to 41 minutes,
inlet port at 220°and detector at 260°,
– a flame-ionisation detector,
– flow rate. 2.4 ml per minute using nitrogen as carrier gas.
Inject 1 µl of the reference solution. The test is not valid unless the resolution between the peaks due to methyl
palmitate and methyl stearate is not less than 5.0. The relative retention time with reference to methyl stearate for
methyl palmitate is about 0.9. The relative standard deviation of methyl stearate and methyl palmitate for replicate
injections is not more than 3.0 per cent.
Inject 1 µl of the reference solution and the test solution.
Calculate the content of stearic acid.

Terazosin Hydrochloride. Page 2194

Water. Line 1
Change from: 7.8 to 8.6 per cent to: 7.0 to 8.6 per cent

Terbutaline Sulphate. Page 2195

Identification. C
Change to: In the test for Related substances, the principal peak in the chromatogram obtained with the test solution
corresponds to the peak due to terbutaline sulphate that in the chromatogram obtained with reference solution (a).

Related substances. Last para,

Change to: Inject the test solution, reference solution (a) and (b). Run the chromatogram 6 times the retention time
of the principal peak. In the chromatogram obtained with the test solution, the area of the peak due to terbutaline
impurity C is not more than twice area of the corresponding peak in the chromatogram obtained with reference
solution (a) (0.2 per cent), the area of other secondary peaks, for each peak is not more than area of the principal
peak in the chromatogram obtained with reference solution (b) (0.2 per cent). The sum of all the secondary peaks
other than terbutaline impurity C is not more than twice the area of the principal peak in the chromatogram obtained
with reference solution (b) (0.4 per cent). Ignore any peak with an area less than 0.1 times the area of the principal
peak in the chromatogram obtained with reference solution (b) (0.02 per cent).

Terbutaline Tablets. Page 2198

Dissolution. Para 1,
Change to: Withdraw a suitable volume of the medium and filter. Carry out the method as described under Assay
beginning at the words “To 5.0 ml add 35 ml of a buffer solution....”. Calculate the content of
(C12H19NO3)2·H2SO4 in the medium from the absorbance obtained from a solution of known concentration of
terbutaline RS prepared in the same manner.

Tramadol Hydrochloride. Page 2245

Specific optical rotation. Line 1
Change from: Specific optical rotation to: Optical rotation

Thiocolchicoside. Page 2213

Bacterial endotoxins. Replace the test with the following

Insert the following before Storage

Thiocolchicoside intended for use in the manufacture of parenteral preparations without a further appropriate
procedure for the removal of bacterial endotoxins complies with the following additional requirement.
Bacterial endotoxins (2.2.3). Not more than 87.5 Endotoxin Unit per mg.
Thiocolchicoside intended for use in the manufacture of parenteral preparations without a further appropriate
sterilisation procedure complies with the following additional requirement.
Sterility (2.2.11). Complies with the test for sterility.

Topiramate. Page 2243

Usual strengths
Change from: 25 mg and 50 mg to: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg and 400 mg
Trimetazidine Hydrochloride. Page 2263
Related substances. Change to:
Related substances. Determine by liquid chromatography (2.4.14).
Test solution. Dissolve 0.2 g of the substance under examination in 50 ml of water.
Reference solution. Dilute 2.0 ml of the test solution to 100.0 ml with water. Dilute 5.0 ml of this solution to 100.0
ml with water.
Chromatographic system
– a stainless steel column15 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
– column temperature. 30º,
– mobile phase: A. a mixture of 35.7 volumes of methanol and 64.3 volumes of a 0.29 per cent w/v solution of
sodium heptanesulphonate, adjusted to pH 3.0 with orthophosphoric acid,
B. methanol,
– a linear gradient programme using the conditions given below,
– flow rate. 1.2 ml per minute,
– spectrophotometer set at 240 nm,
– injection volume. 10 µl.
Time Mobile phase A Mobile phase B
(min.) (per cent v/v) (per cent v/v)
0 - 50 95 → 75 5 → 25
50 - 52 75 → 95 25 → 5
Equilibrate the column for not less than 1 hour with the mobile phase.
Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not
more than 2.0 per cent. The relative retention time with reference to trimetazidine for (2,3,4-
trimethoxyphenyl)methanol (trimetazidine impurity D) is about 0.2, for 2,3,4-trimethoxybenzaldehyde
(trimetazidine impurity C) is about 0.4, for ethyl 4-(2,3,4-trimethoxybenzyl)piperazine-1-carboxylate (trimetazidine
impurity H) is about 0.6, for 1-(3,4,5-trimethoxybenzyl)piperazine (trimetazidine impurity A) and N-
methyltrimetazidine (trimetazidine impurity I) is about 0.9, for 1-(2,4,5-trimethoxybenzyl)piperazine (trimetazidine
impurity E) is about 0.95, for 1-(2,4,6-trimethoxybenzyl) piperazine (trimetazidine impurity F) is about 1.4 and for
1,4-bis(2,3,4-trimethoxybenzyl) piperazine (trimetazidine impurity B) is about 1.8.
Inject the test solution and the reference solution. In the chromatogram obtained with the test solution, the area of
each peak due to trimetazidine impurity A, B, C, D, E, F, H, I multiplied with correction factor 0.55 for impurity B,
0.37 for impurity C and 0.71 for impurity F is not more than the area of the principal peak in the chromatogram
obtained with the reference solution (0.1 per cent), the area of any other secondary peak is not more than the area of
the principal peak in the chromatogram obtained with the reference solution (0.1 per cent). The sum of areas of all
the secondary peaks is not more than twice the area of the principal peak in the chromatogram obtained with the
reference solution (0.2 per cent). Ignore any peak with an area less than 0.5 times the area of the principal peak in
the chromatogram obtained with the reference solution (0.05 per cent).

Valsartan. Page 2286

Identification. Insert the following before test A
“Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.

Test C
Change from: When examined in the range 200 nm to 300 nm (2.4.7), a 0.001 per cent w/v solution in 0.1 M
hydrochloric acid exhibits a maximum at about 248 nm. to: The light absorption of 5 per cent w/v solution in
methanol at 420 nm (2.4.7) is not more than 0.02.

Valsartan and Hydrochlorothiazide Tablets. Page 2287

Usual strengths. Line 2
Change from: 60 mg to: 160 mg

Identification. Reference solution

Change from: Reference solution. A solution containing 0.02 per cent w/v each of valsartan RS and
hydrochlorothiazide RS in acetone. to: Reference solution. A solution equivalent to test concentration of valsartan
RS and hydrochlorothiazide RS in acetone.

Vancomycin Hydrochloride. Page 2289

Vancomycin B.
Change to: Vancomycin B. Determine by liquid chromatography (2.4.14).

NOTE- Use freshly prepared solutions.

Test solution (a). Dissolve 10 mg of the substance under examination in mobile phase A and dilute to 5.0 ml with
mobile phase A.

Test solution (b).Dilute 2.0 ml of test solution (a) to 50.0 ml with mobile phase A.

Test solution (c).Dilute 0.5 ml of test solution (b) to 20.0 ml with mobile phase A.

Reference solution. A 0.05 per cent w/v solution of vancomycin hydrochloride RS in water. Heat at 65° for 24 hours,
allow to cool.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5µm),
- mobile phase: A. a mixture of 1 volume of tetrahydrofuran,7 volumes of acetonitrile and 92 volumes of buffer
solution prepared by diluting 1 ml of triethylamine to 500 ml with water, adjust the pH to 3.2 with orthophosphoric
acid,
B. a mixture of 1 volume of tetrahydrofuran, 29 volumes of acetonitrile and 70 volumes of buffer solution
prepared by diluting 1 ml of triethylamine to 500 ml with water, adjust the pH to 3.2 with orthophosphoric acid,
- a linear gradient programme using conditions given below,
- flow rate.1ml per minute,
- spectrophotometer set at 280 nm,
- injection volume. 20 µl.

Time Mobile phase A Mobile phase B

(in min.) (per cent v/v) (per cent v/v)
0-13 100 0
13-22 100-0 0-100
22-26 0 100

Inject test solution (a), (b), (c) and the reference solution. The test is not valid unless the resolution between the two
principal peaks in the chromatogram obtained with the reference solution is not less than 5.0, signal-to-noise ratio
for the principal peak in the chromatogram obtained with test solution (c) is not less than 5.0 and the tailing factor
for the peak due to vancomycin in the chromatogram obtained with the test solution (b) is not more than 1.6.

Calculate the percentage content of vancomycin B hydrochloride using the following expression:

Ab = area of the peak due to vancomycin B in the chromatogram obtained with test solution (b);
At = sum of the areas of the peaks due to impurities in the chromatogram obtained with test solution (a).

Related substances.
Change to: Related substances. Determine by liquid chromatography (2.4.14), as described under Vancomycin B
with following modifications.

Inject test solution (a), (b) and (c). In the chromatogram obtained with the test solution, the area of any secondary
peak is not more than 4.0 per cent. The sum of areas of all the secondary peaks is not more than 7.0 per cent. Ignore
any peak with an area less than the area of the principal peak in the chromatogram obtained with test solution (c)
(0.1 per cent).

Calculate the percentage content of each impurity using the following expression:

Ai = area of the peak due to an impurity in the chromatogram obtained with test solution (a);
Ab = area of the peak due to vancomycin B in the chromatogram obtained with test solution (b);
At = sum of the areas of the peaks due to impurities in the chromatogram obtained with test solution (a).

Verapamil Hydrochloride. Page 2295

Identification. C
Change to: In the test for Related substances, the principal peak in the chromatogram obtained with the test solution
corresponds to the peak due to verapamil that in the chromatogram obtained with reference solution (a).

Verapamil Tablets. Page 2297

Para 1, line 3
Delete “The tablets may be coated”

Vinblastine Injection. Page 2299

Storage. Lines 1and 2
Change from: Store in sealed containers in a deep freezer (Below -18 º) to: Store in sealed containers at a
temperature of 2º to 8º.

Vincristine Injection. Page 2302

Storage. Lines 1and 2
Change from: Store in sealed containers in a deep freezer (Below -18 º) to: Store in sealed containers at a
temperature of 2º to 8º.

Warfarin Sodium Clathrate. Page 2312

Isopropyl alcohol. After chromatographic system, para 1
Change from: The column temperature may be varied so that the resolution, R, between propan-1-ol and propanol-2
ol is not less than 2.0, the tailing factor. T, for the propan-2-ol is not less than 2.0 the tailing factor T, for the propan-
2-ol peak is not more than 1.5 and the relative standard deviation of the ratio of the area due to the peak of propanol-
2-ol to that due to propan-1-ol for five replicate injections of reference solution (b) is not more than 2.0 per cent. to:
The column temperature may be varied so that the resolution between propan-1-ol and propanol-2-ol is not less than
1.5, the tailing factor for the propan-2-ol is not more than 2.0, the tailing factor for the propan-1-ol is not more than
2.0 and the relative standard deviation of the ratio of the area due to the peak of propanol-2-ol to that due to propan-
1-ol for five replicate injections of reference solution (b) is not more than 2.0 per cent.

Water.
Change from: Not more than 4.0 per cent, determined on 0.75 g. to: Not more than 0.3 per cent, determined on 2.5
g.

Water for Injections in Bulk. Page 2315

Para 2, line 4
Change from: 10 micro-organisms per ml to: 10 micro-organisms per 100 ml

Xylometazoline Nasal Drops. Page 2323

Line 1
Change from: Xylometazoline Hydrochloride Nasal Drops to: Xylometazoline Hydrochloride Nasal Drops;
Xylometazoline Hydrochloride Nasal Solution

Zinc Stearate. Page 2337

Sulphates. Line 1
Change from: 2.5 ml of solution A to: Dilute 1 ml of solution A to 50 ml with water. Dilute 12.5 ml of this solution
to 15 ml with water

Zoledronic Acid. Page 2339

Add synonym “Zoledronic Acid Monohydrate”
Lines 1, 2 and 3
Change to: C5H10N2O7P2. H2O Mol. Wt. 290.1
Zoledronic Acid is [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]diphosphonic acid, monohydrate.

Loss on drying.
Change from: Loss on drying (2.4.19). to: Water (2.3.43).

HERBS AND HERBAL PRODUCTS

Coconut Oil. Page 2492

Description.
Change from: A white or almost white, unctuous mass. to: White to light yellow mass or colourless or light yellow,
clear oil.

VETERINARY MONOGRAPHS

Ivermectin Injection. Page 2663

Assay. Test solution, line 2
Change from: water to: methanol

Reference solution, line 2

Change from: water to: methanol